Oct. 7 Company Quick Takes: Editas-MaxCyte, Goldfinch-Takeda, Prometheus-Takeda, DBV and Galderma

Editas licenses MaxCyte tech to develop engineered cell medicines
Editas Medicine Inc. (NASDAQ:EDIT) licensed non-exclusive clinical and commercial rights to Flow Electroporation technology and ExPERT instruments from MaxCyte Inc. (LSE:MXCT) to develop engineered cell medicines, including EDIT-301, a CRISPR therapy that is in preclinical testing for sickle cell disease and β thalassemia. Editas will develop up to five therapies, including four immuno-oncology therapies. MaxCyte is eligible to receive milestones, sales payments and licensing fees. Details are not disclosed.

Goldfinch licenses CB1 inhibitor for kidney diseases from Takeda
Goldfinch Biopharma Inc. licensed a peripherally restricted cannabinoid receptor 1 (CB1) mAb from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK). Goldfinch will be responsible for development and commercialization to treat rare and metabolic kidney diseases worldwide; Takeda has an option to negotiate Japanese rights before pivotal trials begin. Goldfinch plans to submit an IND for the compound, which it has renamed GFB-024, in 2H20. Financial terms were not disclosed. (see "Kidney is the New Liver").

Prometheus, Takeda in IBD therapy, companion Dx deal
Prometheus Biosciences Inc. partnered with Takeda to develop and commercialize three targeted IBD therapies and companion diagnostics. Prometheus will identify and validate three drug targets and develop and commercialize companion diagnostics for the resulting therapies. Prometheus will receive an undisclosed upfront payment and is eligible to receive up to $420 million in development, regulatory and commercial milestones, plus royalties.

FDA approval for Aklief acne cream
FDA approved Galderma Laboratories L.P.’s Aklief trifarotene cream 0.005% for acne. Aklief is the first new retinoid molecule approved by FDA for acne in more than two decades, according to the company.

Viaskin Peanut back under FDA review
FDA accepted a BLA from DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) for the peanut allergy therapy Viaskin Peanut for children between the ages of 4 and 11. The PDUFA date is Aug. 5, 2020. According to the company, FDA plans to hold an advisory committee meeting to discuss the application. Viaskin Peanut is a patch that delivers peanut proteins epicutaneously.

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE